[7-year experience in usage of mirapex in patients with different forms of primary parkinsonism].
The results of mirapex (pramipexol) treatment of 402 patients with Parkinson's disease and juvenile parkinsonism during the period from 6 months to 7 years are summarized. Mirapex was used in monotherapy as well as in combination with levadopa and other antiparkinsonic drugs. The drug was well tolerated and effective in rest tremor, hypokinesia, muscle rigidity and depression, the more pronounced effect being seen at the early stage of the disease. The use of mirapex allows an effective control of motor fluctuations developing during long-term continuous levodopa therapy. The results obtained characterize mirapex as a drug of choice in the treatment of juvenile parkinsonism. In case of a break in mirapex treatment, the recommencement of treatment usually is not accompanied by reduced sensitivity to drug effect.
Illarioshkin
S N
SN
Ivanova-Smolenskaia
I A
IA
Zagorovskaia
T B
TB
Karabanov
A V
AV
Poleshchuk
V V
VV
Markova
E D
ED
Karpova
E A
EA
Polevaia
E V
EV
Bagyeva
G Kh
GKh
Timerbaeva
S L
SL
Nurmanova
Sh A
ShA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D052160:Benzothiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D000077487:Pramipexole; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D017447:Receptors, Dopamine D1; D000077487:Pramipexole